SCHEMBL30830689

SCHEMBL30830689

CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccc(C(=O)N3CCN(Cc4cnn(C5CCC(=O)NC5=O)c4)CC3)cc2)C1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 19/20 0.50
▸ BRD9 Q9H8M2 3/20 0.50
▸ KAT2A Q92830 2/20 0.50
▸ BRD1 O95696 1/20 0.50
▸ ACHE P22303 1/20 0.50
▸ BRPF1 P55201 1/20 0.50
▸ BPTF Q12830 1/20 0.50
▸ BRD7 Q9NPI1 1/20 0.50
▸ BAZ2B Q9UIF8 1/20 0.50
▸ BRPF3 Q9ULD4 1/20 0.50
▸ IKZF2 Q9UKS7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830541 0.89 KAT2B (0.52) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830904 0.87 KAT2B (0.49) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830986 0.87 KAT2B (0.49) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30831054 0.86 KAT2B (0.52) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830506 0.86 KAT2B (0.51) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830927 0.85 IKZF2 (0.47) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830500 0.84 KAT2B (0.54) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830518 0.84 KAT2B (0.54) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830571 0.83 KAT2B (0.55) KAT2BBRD9KAT2ABRD1ACHE
SCHEMBL30830684 0.83 KAT2B (0.56) KAT2BBRD9KAT2ABRD1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback